LivaNova’s OSPREY Trial Success Drives Buy Recommendation Amid Market Potential
Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...
Business Insider12 天
LivaNova’s Promising OSPREY Study Results Propel Buy Rating Amid Strong OSA Market Potential
Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on LIVN stock, giving a Buy rating yesterday. Anthony Petrone’s rating is based on several promising developments ...